132 related articles for article (PubMed ID: 32075400)
1. OlympiAD trial: moving to a next level of treatment for patients with BRCA mutation and her2-negative metastatic breast cancer.
Sanchez AM; Orlandi A; Franceschini G; De Lauretis F; Terribile D; Franco A; Masetti R
Ann Palliat Med; 2020 Mar; 9(2):510-511. PubMed ID: 32075400
[No Abstract] [Full Text] [Related]
2. New Treatment for BRCA-Mutated Metastatic Breast Cancer.
Aschenbrenner DS
Am J Nurs; 2018 May; 118(5):21-22. PubMed ID: 29698273
[No Abstract] [Full Text] [Related]
3. Olaparib Keeps Hereditary Breast Tumors in Check.
Cancer Discov; 2017 Aug; 7(8):OF10. PubMed ID: 28583909
[TBL] [Abstract][Full Text] [Related]
4. [Case of Recurrent Breast Cancer with BRCA2 Mutation Successfully Treated with Olaparib Therapy].
Yoneda H; Shimizu Y; Masuda R
Gan To Kagaku Ryoho; 2020 May; 47(5):815-818. PubMed ID: 32408326
[TBL] [Abstract][Full Text] [Related]
5. Olaparib for the treatment of breast cancer.
Griguolo G; Dieci MV; Guarneri V; Conte P
Expert Rev Anticancer Ther; 2018 Jun; 18(6):519-530. PubMed ID: 29582690
[TBL] [Abstract][Full Text] [Related]
6. Some subgroups might get less benefit from adjuvant olaparib trial in high-risk, HER2-negative and germline BRCA2 BRCA1- or BRCA2-mutated early breast cancer patients.
Altundag K
J BUON; 2021; 26(5):2202. PubMed ID: 34761636
[No Abstract] [Full Text] [Related]
7. PARP inhibitors in cancer: moving beyond BRCA.
Telli ML
Lancet Oncol; 2011 Sep; 12(9):827-8. PubMed ID: 21862406
[No Abstract] [Full Text] [Related]
8. Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
Armstrong AC; Clay V
Future Oncol; 2019 Jul; 15(20):2327-2335. PubMed ID: 31304797
[TBL] [Abstract][Full Text] [Related]
9. BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?
Sahin I; Ararat E; Altundag K
J BUON; 2011; 16(1):184-5. PubMed ID: 21674877
[No Abstract] [Full Text] [Related]
10. Made-to-measure medicine: BRCA and gynaecological cancer.
Foulkes WD
Lancet Oncol; 2014 Jul; 15(8):783-5. PubMed ID: 24882435
[No Abstract] [Full Text] [Related]
11. [Olaparib in ovarian cancer with BRCA mutation].
Pujade-Lauraine É; Combe P
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S82-4. PubMed ID: 26118881
[TBL] [Abstract][Full Text] [Related]
12. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
13. To BRCA or Not to PALB.
McNamara MG; Lamarca A; Hubner RA; Valle JW
J Clin Oncol; 2015 Aug; 33(23):2581-2. PubMed ID: 26124473
[No Abstract] [Full Text] [Related]
14. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
15. Olaparib for the treatment of breast cancer.
Robert M; Frenel JS; Gourmelon C; Patsouris A; Augereau P; Campone M
Expert Opin Investig Drugs; 2017 Jun; 26(6):751-759. PubMed ID: 28395540
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Robson M; Ruddy KJ; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Li W; Tung N; Armstrong A; Delaloge S; Bannister W; Goessl C; Degboe A; Hettle R; Conte P
Eur J Cancer; 2019 Oct; 120():20-30. PubMed ID: 31446213
[TBL] [Abstract][Full Text] [Related]
17. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
18. Olaparib in platinum-sensitive ovarian cancer.
Kaji D; Miura Y; Takano T
N Engl J Med; 2012 Jul; 367(2):179; author reply 179-80. PubMed ID: 22784123
[No Abstract] [Full Text] [Related]
19. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.
Le D; Gelmon KA
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):833-839. PubMed ID: 30118334
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibition in BRCA-mutated breast and ovarian cancers.
Chan SL; Mok T
Lancet; 2010 Jul; 376(9737):211-3. PubMed ID: 20656109
[No Abstract] [Full Text] [Related]
[Next] [New Search]
